Clearside Biomedical Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Clearside Biomedical stock.
View analyst ratings for Clearside Biomedical or view top-rated stocks.

Wall Street analysts have given Clearside Biomedical a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Clearside Biomedical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Clearside Biomedical is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Clearside Biomedical.

Clearside Biomedical, Inc. (NASDAQ:CLSD) issued its quarterly earnings results on Sunday, May, 16th. The company reported ($0.13) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.03. The firm had revenue of $0.03 million for the quarter, compared to the consensus estimate of $3.20 million. Clearside Biomedical had a negative net margin of 591.23% and a negative trailing twelve-month return on equity of 220.12%.
View Clearside Biomedical's earnings history.

Clearside Biomedical's stock was trading at $2.59 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CLSD shares have increased by 86.9% and is now trading at $4.84.
View which stocks have been most impacted by COVID-19.

4 equities research analysts have issued 1-year target prices for Clearside Biomedical's stock. Their forecasts range from $9.00 to $18.00. On average, they anticipate Clearside Biomedical's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 189.3% from the stock's current price.
View analysts' price targets for Clearside Biomedical or view top-rated stocks among Wall Street analysts.

Some companies that are related to Clearside Biomedical include Dyne Therapeutics (DYN), Phathom Pharmaceuticals (PHAT), Humanigen (HGEN), Vanda Pharmaceuticals (VNDA), MannKind (MNKD), PyroGenesis Canada (PYR), Akero Therapeutics (AKRO), Pliant Therapeutics (PLRX), Kinnate Biopharma (KNTE), Ocular Therapeutix (OCUL), Rhythm Pharmaceuticals (RYTM), Kiniksa Pharmaceuticals (KNSA), Dynavax Technologies (DVAX), Connect Biopharma (CNTB) and Trillium Therapeutics (TRIL).
View all of CLSD's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Clearside Biomedical investors own include Northwest Biotherapeutics (NWBO), Ocular Therapeutix (OCUL), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Melinta Therapeutics (MLNT), OrganiGram (OGI), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Miragen Therapeutics (MGEN) and Gran Tierra Energy (GTE).

(CLSD) raised $50 million in an initial public offering on Thursday, June 2nd 2016. The company issued 7,200,000 shares at a price of $7.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.

Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD."

Clearside Biomedical's stock is owned by a number of retail and institutional investors. Top institutional investors include RTW Investments LP (7.31%), Acuta Capital Partners LLC (2.80%), BlackRock Inc. (1.52%), Renaissance Technologies LLC (0.98%), Geode Capital Management LLC (0.63%) and Morgan Stanley (0.62%). Company insiders that own Clearside Biomedical stock include Bradford T Whitmore, Charles A Deignan, Clay Thorp, George M Lasezkay, Nancy J Hutson and William D Humphries.
View institutional ownership trends for Clearside Biomedical.

CLSD stock was acquired by a variety of institutional investors in the last quarter, including Acuta Capital Partners LLC, Morgan Stanley, RTW Investments LP, Assenagon Asset Management S.A., Millennium Management LLC, QS Investors LLC, BlackRock Inc., and Renaissance Technologies LLC. Company insiders that have bought Clearside Biomedical stock in the last two years include Bradford T Whitmore, Charles A Deignan, George M Lasezkay, Nancy J Hutson, and William D Humphries.
View insider buying and selling activity for Clearside Biomedical or or view top insider-buying stocks.

Shares of CLSD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CLSD stock can currently be purchased for approximately $4.84.

Clearside Biomedical has a market capitalization of $278.68 million and generates $7.89 million in revenue each year. The company earns $-18,210,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis.

Clearside Biomedical employs 33 workers across the globe.

The official website for Clearside Biomedical is www.clearsidebio.com.

Clearside Biomedical is headquartered at 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005.

Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The company can be reached via phone at 678-270-3631 or via email at [email protected]